A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia

Phase 3

Recruiting

• Conditions: Schizophrenia
• Interventions: Other: Placebo; Drug: SEP-363856

• Registration Number: NCT06894212
• Lead Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.

Brief Summary

This is a Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Determine the the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants with Schizophrenia

Detailed Description

Not available

Study Timeline

• Study Start: 2025-02-25
• Study First Submitted: 2025-02-27
• Study First Submitted QC: 2025-03-24
• Study First Posted: 2025-03-25
• Status Verified: 2025-07
• Last Update Submitted: 2025-07-22
• Last Update Posted: 2025-07-25
• Primary Completion: 2028-04-06
• Study Completion: 2028-08-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 522

Inclusion Criteria

Male or female participants between 18 to 65 years of age (inclusive) at the time of consent.

Participant has an identified reliable informant (eg, caregiver, relative, friend, case worker, residential treatment staff).

Participant is experiencing an acute exacerbation or relapse of symptoms, with onset ≤ 2 months prior to screening

1. The participant requires hospitalization for this acute exacerbation or relapse of symptoms.
2. If already an inpatient at screening, has been hospitalized for less than 2 weeks for the current exacerbation at the time of screening.

Participants who are experiencing an acute exacerbation of psychotic symptoms and marked deterioration of usual function as demonstrated by meeting ALL of the following criteria at the screening and baseline visits:

1. Participant must have a PANSS total score ≥ 80

   AND

2. Participant must have a CGI-S score ≥ 4.

Participants who have received previous outpatient antipsychotic treatment at an adequate dose (minimal recommended dose for the treatment of schizophrenia according to the manufacturer labeling) for an adequate duration (at least 6 weeks) and who showed a previous good response.

Key

Exclusion Criteria

Sexually active participants or persons of childbearing potential who do not agree to practice 2 different clinical trial sponsor approved methods of birth control or remain abstinent during the course of the trial and for 30 days after the last dose of study drug.

Participant has a current DSM-5 diagnosis or presence of symptoms consistent with a DSM-5 diagnosis other than schizophrenia.

Participant has had psychiatric hospitalization(s) for more than 30 days (cumulative) during the 90 days prior to screening.

Participant has previously received SEP-363856 or was previously enrolled in a SEP-363856 clinical study

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	Placebo
SEP-363856 75 mg	SEP-363856	SEP-363856 75 mg/day
SEP-363856 100 mg	SEP-363856	SEP-363856 100 mg/day

Primary Outcome Measures

Name	Time	Method
The change from baseline in Positive And Negative Syndrome Scale (PANSS) total score at Week 6	Baseline to Week 6	To evaluate the efficacy of SEP-363856 (75 and 100 mg/day) compared with placebo in acutely psychotic participants with schizophrenia.

Secondary Outcome Measures

Name	Time	Method
Clinical Global Impression-Severity (CGI-S)	Baseline to Week 6	Change from baseline in CGI-S score at Week 6.

Trial Locations

Locations (36)

Premier Clinical Research Institute - Site #150; 🇺🇸 Miami, Florida, United States

Eastern Clinical Research Associates - Site # 156; 🇺🇸 New Orleans, Louisiana, United States

Pillar Clinical Research LLC - Bentonville Site # 145; 🇺🇸 Bentonville, Arkansas, United States

Pillar Clinical Research (Little Rock AR) Site #153; 🇺🇸 Little Rock, Arkansas, United States

Woodland International Research Group Site #141; 🇺🇸 Little Rock, Arkansas, United States

Woodland Research Northwest Site # 138; 🇺🇸 Rogers, Arkansas, United States

Clinical Innovations, Inc. dba CITrials (Bellflower) Site #131; 🇺🇸 Bellflower, California, United States

ProScience Research Group Site #134; 🇺🇸 Culver City, California, United States

CenExel CNS - Garden Grove (Collaborative Neuroscience Research) Site #123; 🇺🇸 Garden Grove, California, United States

Synergy San Diego Site #128; 🇺🇸 Lemon Grove, California, United States

Scroll for more (26 remaining)